After months of anticipation the hepatitis C price wars are finally getting under way As of today Express Scripts the largest pharmacy benefits manager in the US is making the newly approved treatment from AbbVie its exclusive option for patients with the most prevalent form of the chronic disease which is known as genotype  This covers about  of the estimated  million Americans who are infected The decision will quickly change the calculus for one of the most closely watched markets in the pharmaceutical industry since other payers will now look for similar deals Some Wall Street analysts expect worldwide sales of hepatitis C treatments led by a pair of medications sold by Gilead Sciences to reach as much as  billion in revenue next year thanks to pentup demand for new treatments